Dagna, L., Corti, A., Langheim S., Guglielmi, B., De Cobelli, F., Doglioni, C., Fragasso, G., Sabbadini, M.G. and Ferrarini, M. (2012) Tumor Necrosis Factor α as a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients with Infliximab. Journal of Clinical Oncology, 30, e286-e290.
https://doi.org/10.1200/JCO.2012.41.9911

has been cited by the following article:

• TITLE: Thirty-Four Months Control of Frail Patient with Multisystemic Affection Proved Erdheim Chester Disease: A Case Report

  AUTHORS: Emad Mohsen Barsoum, Fiby Samir Boules, May Gamal Ashour, Mohsen Samy Barsoum

  KEYWORDS: Erdheim-Chester Disease, Histiocytoses, Non-Langerhans Cell Histiocytoses

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.12, December 13, 2021

  ABSTRACT: Erdheim-Chester disease (ECD) is a rare non-Langerhans form of histiocytosis characterized by multisystemic involvement. We report a case of a 51-year-old male patient treated with pegylated IFN-α in a monthly schedule with low-dose prednisolone and achieved 34 months of control with minimal side effects.